Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Aminolevulinic Acid HCl
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Alpheus Announces Positive Glioma Treatment Phase 1/2 Results
Details : Low-Intensity Diffuse Ultrasound with the sensitizing agent, oral 5-aminolevulinic acid (5-ALA) is being investigated in patients with recurrent or refractory high-grade gliomas.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 24, 2024
Lead Product(s) : Aminolevulinic Acid HCl
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?